Relations between large artery structure and function and aldosterone

Journal of Hypertension

Volumn 29, Issue 9, 2011, Pages 1676-1683

  Safar, Michel E ^a,b,c   Millasseau, Sandrine ^d   Mahmud, Azra ^c   Blacher, Jacques ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Assistance Publique Hô Pitaux de Paris   (France)

^c HÔTEL DIEU   (France)

^d Pulse Wave Consulting   (France)

Author keywords

aldosteronism; arterial stiffness; hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; MINERALOCORTICOID RECEPTOR; PLACEBO; QUINAPRIL; SPIRONOLACTONE;

ADRENAL CORTEX ADENOMA; ADVENTITIA; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; AORTA; AORTA WALL; ARTERIAL STIFFNESS; ARTERY ENDOTHELIUM; ARTERY INJURY; BIOMECHANICS; BLOOD FLOW VELOCITY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; GENOTYPE; HEART INJURY; HUMAN; HYPERTENSION; KIDNEY INJURY; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN;

EID: 80051945493     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328349adf6     Document Type: Review

References (86)

1. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction-a paradigm shift. J Hypertens 2001; 19:829-842. (Pubitemid 32436945)
2. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001; 3:240-248.
3. Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003; 107:2512-2518. (Pubitemid 36605237)
4. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47:312-318. (Pubitemid 43740260)
5. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583-585. (Pubitemid 18263202)
6. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268-275. (Pubitemid 17095145)
7. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA 1998; 95:2973-2978.
8. Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Do human vascular endothelial cells produce aldosterone? Endocrinology 2004; 145:3626-3629. (Pubitemid 39037546)
9. Wehling M. Nongenomic actions of steroid hormones. Trends Endocrinol Metab 1994; 5:347-353. (Pubitemid 24371383)
10. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83:3517-3522. (Pubitemid 28500882)
11. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res 1995; 76:973-979.
12. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93:2578-2583. (Pubitemid 24177174)
13. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269:24316-24320.
14. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81:2797-2800. (Pubitemid 26323867)
15. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29:45-48. (Pubitemid 27078339)
16. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 2006; 47:634-635. (Pubitemid 43740226)
17. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol 1977; 232:C165-C173. (Pubitemid 8134015)
18. Tait JF, Little B, Tait SA, Flood C, Bougas J. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965; 25:219-228.
19. Fraser R, Brown JJ, Lever AF, Mason PA, Robertson JI. Control of aldosterone secretion. Clin Sci (Lond) 1979; 56:389-399. (Pubitemid 10156569)
20. Cowley AW Jr, Lohmeier TE. The relationship between body fluid volume, sodium ion concentration, and sensitivity to pressor effect of angiotensin II in dogs. Circ Res 1978; 42:503-511. (Pubitemid 8322538)
21. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005; 18:657-665. (Pubitemid 40692433)
22. Tarazi RC, Ibrahim MM, Bravo EL, Dustan HP. Hemodynamic characteristics of primary aldosteronism. N Engl J Med 1973; 289:1330-1335.
23. London GM, Safar ME, Weiss YA, Corvol PL, Menard JE, Simon AC, Milliez PL. Relationship of plasma renin activity and aldosterone levels with hemodynamic functions in essential hypertension. Arch Intern Med 1977; 137:1042-1047. (Pubitemid 9006742)
24. Safar ME, Simon AC, Dard SA, Parlier HR, Pauleau NE, Vincent ML, Sassard JE. Aldosterone in sustained essential hypertension. Clin Endocrinol (Oxf) 1982; 16:77-88. (Pubitemid 12200730)
25. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000; 57:1408-1411. (Pubitemid 30207899)
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321. (Pubitemid 36384098)
27. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700-2706.
28. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104:467-472. (Pubitemid 32678279)
29. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17:1152-1156. (Pubitemid 27260336)
30. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37:662-667.
31. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004; 313:812-817. (Pubitemid 38021903)
32. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995; 29:27-32.
33. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597. (Pubitemid 30094728)
34. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103:425-431. (Pubitemid 35193248)
35. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109:2857-2861. (Pubitemid 38780298)
36. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 2006; 7:31-39. (Pubitemid 43891243)
37. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 2007; 104:16281-16286. (Pubitemid 350099397)
38. Oberleithner H. Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005; 67:1680-1682. (Pubitemid 40577700)
39. Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs 2008; 9:963-969.
40. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15:264-272. (Pubitemid 30496722)
41. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26:971-978.
42. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26:671-677.
43. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106:2848-2853. (Pubitemid 35396986)
44. Bezie Y, Lamaziere JM, Laurent S, Challande P, Cunha RS, Bonnet J, Lacolley P. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998; 18:1027-1034. (Pubitemid 28323586)
45. Bardy N, Merval R, Benessiano J, Samuel JL, Tedgui A. Pressure and angiotensin II synergistically induce aortic fibronectin expression in organ culture model of rabbit aorta. Evidence for a pressure-induced tissue reninangiotensin system. Circ Res 1996; 79:70-78.
46. Takasaki I, Chobanian AV, Sarzani R, Brecher P. Effect of hypertension on fibronectin expression in the rat aorta. J Biol Chem 1990; 265:21935-21939. (Pubitemid 120014245)
47. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449. (Pubitemid 34225390)
48. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart ofDOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 2002; 39:679-684. (Pubitemid 34165205)
49. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068. (Pubitemid 26293326)
50. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003; 41:666-673. (Pubitemid 36223335)
51. Seccia TM, Maniero C, Belloni AS, Guidolin D, Pothen P, Pessina AC, RossiGP. Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis. J Hypertens 2008; 26:2022-2029.
52. Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173:1617-1627.
53. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
54. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248. (Pubitemid 40523144)
55. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40:23-27. (Pubitemid 34755974)
56. Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. Am J Hypertens 2008; 21:742-747. (Pubitemid 351913613)
57. Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004; 19:774-777. (Pubitemid 38455644)
58. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50-55. (Pubitemid 40187349)
59. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41:326-333.
60. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51:161-167. (Pubitemid 351159920)
61. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63:1791-1800. (Pubitemid 36513325)
62. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res 2002; 90:1316-1324. (Pubitemid 34787414)
63. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, London GM. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 1998; 13:375-383. (Pubitemid 28062199)
64. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51:1678-1695. (Pubitemid 27252735)
65. Lacolley P, Safar ME, Regnault V, Frohlich ED. Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. Am J Physiol Heart Circ Physiol 2009; 297:H1567-H1575.
66. Blacher J, Kakou A, Lacombe JM, Safar ME. Preferential association of aldosterone synthase gene polymorphism with central blood pressure and wave reflections in hypertensive individuals. J Hum Hypertens 2010; 24:291-299.
67. Safar ME, Lajemi M, Rudnichi A, Asmar R, Benetos A. Angiotensinconverting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension. Arterioscler Thromb Vasc Biol 2004; 24:782-786. (Pubitemid 38451620)
68. Mitchell GF, DeStefano AL, LarsonMG, Benjamin EJ, Chen MH, Vasan RS, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. Circulation 2005; 112:194-199. (Pubitemid 40982301)
69. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971; 27:335-346.
70. Safar ME, Cattan V, Lacolley P, Nzietchueng R, Labat C, Lajemi M, et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23:1159-1166. (Pubitemid 40862719)
71. Pojoga L,Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, Benetos A. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998; 11:856-860. (Pubitemid 28351020)
72. White PC, Hautanen A, Kupari M. Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. Endocr Res 1998; 24:797-804. (Pubitemid 29016482)
73. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 88 (Suppl 1):107-124. (Pubitemid 23226442)
74. Ylitalo A, Airaksinen KE, Hautanen A, Kupari M, CarsonM, Virolainen J, et al. Baroreflex sensitivity and variants of the renin angiotensin system genes. J Am Coll Cardiol 2000; 35:194-200. (Pubitemid 30061280)
75. Rajput C, Makhijani K, Norboo T, Afrin F, Sharma M, Pasha ST, Pasha MA. CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. J Hypertens 2005; 23:79-86. (Pubitemid 40128984)
76. Stolarz K, Staessen JA, Kawecka-Jaszcz K, Brand E, Bianchi G, Kuznetsova T, et al. Genetic variation in CYP11B2 and AT1R influences heart rate variability conditional on sodium excretion. Hypertension 2004; 44:156-162. (Pubitemid 39014232)
77. Wojciechowska W, Staessen JA, Stolarz K, Nawrot T, Filipovsky J, Ticha M, et al. Association of peripheral and central arterial wave reflections with the CYP11B2-344C allele and sodium excretion. J Hypertens 2004; 22:2311-2319. (Pubitemid 39620281)
78. Safar ME, Thuilliez C, Richard V, Benetos A. Pressureindependent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res 2000; 46:269-276. (Pubitemid 30204599)
79. Monahan KD, Leuenberger UA, Ray CA. Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol 2007; 292:H190-H197. (Pubitemid 46105178)
80. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, LondonGM, Safar ME. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10:1326-1334. (Pubitemid 28078735)
81. Duprez DA, De BuyzereML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19:1371-1376. (Pubitemid 28427139)
82. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensinconverting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22:17-22. (Pubitemid 29192364)
83. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41:1021-1026. (Pubitemid 36548598)
84. Safar ME, Avolio A. Aldosterone antagonism and arterial stiffness. Hypertension 2004; 43:e3; author reply e3.
85. Connell JM, Fraser R, MacKenzie S, Davies E. Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension 2003; 41:993-999. (Pubitemid 36548592)
86. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18:1984-1992. (Pubitemid 37220302)